Exploring bat-inspired cyclic tryptophan diketopiperazines as ABCB1 Inhibitors.

Chemotherapy-induced drug resistance remains a major cause of cancer recurrence and patient mortality. ATP binding cassette subfamily B member 1 (ABCB1) transporter overexpression in tumors contributes to resistance, yet current ABCB1 inhibitors have been unsuccessful in clinical trials. To address this challenge, we propose a new strategy using tryptophan as a lead molecule for developing ABCB1 inhibitors. Our idea stems from our studies on bat cells, as bats have low cancer incidences and high ABCB1 expression. We hypothesized that potential ABCB1 substrates in bats could act as competitive inhibitors in humans. By molecular simulations of ABCB1-substrate interactions, we generated a benzylated Cyclo-tryptophan (C3N-Dbn-Trp2) that inhibits ABCB1 activity with efficacy comparable to or better than the classical inhibitor, verapamil. C3N-Dbn-Trp2 restored chemotherapy sensitivity in drug-resistant human cancer cells with no adverse effect on cell proliferation. Our unique approach presents a promising lead toward developing effective ABCB1 inhibitors to treat drug-resistant cancers.

Kalium channelrhodopsins effectively inhibit neurons.

The analysis of neural circuits has been revolutionized by optogenetic methods. Light-gated chloride-conducting anion channelrhodopsins (ACRs)-recently emerged as powerful neuron inhibitors. For cells or sub-neuronal compartments with high intracellular chloride concentrations, however, a chloride conductance can have instead an activating effect. The recently discovered light-gated, potassium-conducting, kalium channelrhodopsins (KCRs) might serve as an alternative in these situations, with potentially broad application. As yet, KCRs have not been shown to confer potent inhibitory effects in small genetically tractable animals. Here, we evaluated the utility of KCRs to suppress behavior and inhibit neural activity in Drosophila, Caenorhabditis elegans, and zebrafish. In direct comparisons with ACR1, a KCR1 variant with enhanced plasma-membrane trafficking displayed comparable potency, but with improved properties that include reduced toxicity and superior efficacy in putative high-chloride cells. This comparative analysis of behavioral inhibition between chloride- and potassium-selective silencing tools establishes KCRs as next-generation optogenetic inhibitors for in vivo circuit analysis in behaving animals.

α-mangostin derivatives ameliorated mouse DSS-induced chronic colitis via regulating Th17/Treg balance.

Th17 cell, an important subpopulation of helper T cell, plays an important role in the development of inflammatory bowel disease (IBD) and is thought to be a potential target for the treatment of IBD. In our previous study, we demonstrated that α-mangostin could relieve lupus nephritis via inhibiting Th17 cell function. In our preliminary study, we obtained four derivatives by adding chemical modification of α-mangostin which could also inhibit Th17 cell differentiation in vitro. In this study, we constructed a chronic IBD mouse model and demonstrated the therapeutic effects of α-mangostin and its derivatives as therapeutic agents for IBD. In compounds treating groups, intestinal inflammation showed significant improvement in symptoms which included weight loss, high disease activity index, colon length shorten and the change of intestinal flora. We also found that compounds could effectively either suppress the number of Th17 cell or increase the number of Treg cell detected by flow cytometry, thus reducing the Th17/Treg ratio and suppressing the level of intestinal inflammation. Notably, IL17-F levels, rather than IL17-A, were reduced in the colon of mice of compounds treating groups. Thus, α-mangostin and its derivatives ameliorate DSS-induced chronic colitis in mice by regulating Th17/Treg balance to alleviate intestinal inflammation and can modulate the intestinal microbial community. These results suggest that α-mangostin and its derivatives may be the new therapeutic option for chronic colitis.

Catalytic ozonation of dimethyl phthalate over cerium supported on activated carbon.

Cerium supported on activated carbon (Ce/AC), which was prepared by dipping method, was employed to degrade dimethyl phthalate (DMP) in water. The mineral matter present in the activated carbon positively contributes to its activity to enhance DMP ozonation process. A higher dipping Ce(NO(3))(3) concentration and calcination process increase its microporous volume and surface area, and decreases its exterior surface area. The catalytic activity reaches optimal when 0.2% (w/w) cerium is deposited on activated carbon. Ce/AC catalyst was characterized by XRD, SEM and BET. The presence of either activated carbon or Ce/AC catalyst considerably improves their degradation and mineralization in the ozonation of DMP. During the ozonation (50mg/h ozone flow rate) of a 30 mg/L DMP (initial pH 5.0) with the presence of Ce/AC catalyst, TOC removal rate reaches 68% at 60 min oxidation time, 48% using activated carbon as catalyst, only 22% with ozonation alone. The presence of tert-butanol (a well known OH radical scavenger) strongly inhibits DMP degradation by activated carbon or Ce/AC catalytic ozonation. TOC removal rate follows the second-order kinetics model well. In the ozonation of DMP with 50mg/h ozone flow rate, its mineralization rate constant with the presence of Ce/AC catalyst is 2.5 times higher than that of activated carbon, 7.5 times higher than that of O(3) alone. Ce/AC catalyst shows the better catalytic activity and stability based on 780 min sequential reaction in the ozonation of DMP. Ce/AC was a promising catalyst for ozonizing organic pollutants in the aqueous solution.